These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8352267)

  • 21. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
    Provenzano R; Bhaduri S; Singh AK;
    Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once weekly treatment with epoetin-beta.
    Locatelli F
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi26-30. PubMed ID: 15958823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
    Lui SF; Law CB; Ting SM; Li P; Lai KN
    Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta.
    Gertz B; Kes P; Essaian A; Bias P; Buchner A; Zellner D
    Curr Med Res Opin; 2012 Jul; 28(7):1101-10. PubMed ID: 22533679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythropoietin 1991--an overview.
    Eschbach JW
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):3-9. PubMed ID: 1928076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential cost savings of erythropoietin administration in end-stage renal disease.
    Hynes DM; Stroupe KT; Greer JW; Reda DJ; Frankenfield DL; Kaufman JS; Henderson WG; Owen WF; Rocco MV; Wish JB; Kang J; Feussner JR
    Am J Med; 2002 Feb; 112(3):169-75. PubMed ID: 11893342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis.
    Goodkin DA; Gimenez LF; Graber SE; Van Stone JC; Egrie JC; Okamoto DM
    Clin Nephrol; 1999 Jun; 51(6):367-72. PubMed ID: 10404697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythropoietin therapy in patients with chronic renal failure.
    Pinevich AJ; Petersen J
    West J Med; 1992 Aug; 157(2):154-7. PubMed ID: 1441466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subcutaneous erythropoietin therapy: efficacy and economic implications.
    Kaufman JS
    Am J Kidney Dis; 1998 Dec; 32(6 Suppl 4):S147-51. PubMed ID: 9892382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of anemia in patients after long term hemodialysis with human recombinant erythropoietin].
    Boratyńska M; Mazanowska O; Szewczyk Z
    Pol Merkur Lekarski; 1996 Nov; 1(5):329-31. PubMed ID: 9273209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-weekly epoetin-beta in renal anemia: the clinical evidence.
    Albertazzi A
    Contrib Nephrol; 2002; (137):408-11. PubMed ID: 12101986
    [No Abstract]   [Full Text] [Related]  

  • 35. Dose tailoring strategies in haemodialysis patients: a discussion of case histories.
    Kleophas W
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi31-6. PubMed ID: 15958825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
    Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients.
    Cody J; Daly C; Campbell M; Donaldson C; Grant A; Khan I; Vale L; Wallace S; MacLeod A
    Cochrane Database Syst Rev; 2002; (4):CD003895. PubMed ID: 12519614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.
    Carlini R; Obialo CI; Rothstein M
    Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.
    Garton JP; Gertz MA; Witzig TE; Greipp PR; Lust JA; Schroeder G; Kyle RA
    Arch Intern Med; 1995 Oct; 155(19):2069-74. PubMed ID: 7575066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study.
    Haag-Weber M; Eckardt KU; Hörl WH; Roger SD; Vetter A; Roth K
    Clin Nephrol; 2012 Jan; 77(1):8-17. PubMed ID: 22185963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.